Billionaires set to take the trip to psychedelics

LONDON: The drugs use to treat a range of mental health conditions is now starting to attract serious investors.

Former investment banker Peter Hunt never did drugs when he was younger. His interest in psychedelics started later in life. That’s when he became intrigued about research into psilocybin – found in magic mushrooms – and MDMA to treat anxiety, depression and post-traumatic stress disorder as part of his post-banking philanthropic work helping the disadvantaged.

A stickler for analysis, Hunt and his wife, opera singer Tania de Jong, went to the Netherlands to undergo the therapy to determine first-hand if the treatments had merit. Hunt was sold.

“I never did any of this when I was younger, so I always assumed drugs were bad. Then I went through the experience and I found it extraordinary. I am not advocating people go out there and take the stuff recreationally. In the right context, it is an incredibly safe and very effective therapy,” says Hunt, who sold out of investment bank Caliburn in 2009. “In five years’ time, they will be seen as a perfectly normal part of our mental health armoury.”

In 2018, Hunt and de Jong established Mind Medicine Australia, which is trying to persuade regulators to legalise psychedelics for therapeutic use in clinical settings. It is also involved in research and training, and aims to train 450 clinicians by the end of this year.

To the surprise of many in the healthcare industry, including Mind Medicine’s critics, their lobbying paid off. Australia became the first country to legalise the medical use of psychedelics when the Therapeutic Goods Administration announced changes to the scheduling of psilocybin and MDMA in February last year.

The decision has divided the medical community, with Mind Medicine’s critics accusing it of aggressive lobbying. Advocates hail the impact the drugs are having on helping sufferers, many of whom are at risk of suicide, when all else has failed. But the sceptics say the approval process has moved too quickly, more trials are needed and the safety of some patients is at risk.

“I find it flabbergasting, and it would never have happened in any other field of medicine,” says Susan Rossell, a cognitive neuropsychologist at Swinburne University’s Centre for Mental Health.

“I am not saying I don’t think this has promise, but I think it needs proper investigation. We just don’t understand the risk profile.”

Advocates disagree, saying the results so far are positive and the process – which involves two therapists sitting with patients for eight hours or more when they take the treatments – is strictly regulated. Prescribing is limited to approved psychiatrists. The TGA permits MDMA, or ecstasy, for the treatment of PTSD, while psilocybin can exclusively be used for treatment-resistant depression.

The decision has triggered a wave of investment into what some in mainstream medicine still view as an unorthodox way to treat mental illness. Australia’s first psychedelic treatment clinics opened this year, the son of a Canadian billionaire last month started importing legally manufactured psychedelic drugs, and big names in business including billionaires Andrew Forrest and Gina Rinehart are pouring money into the fledgling industry. There are clinics in Sydney, Melbourne and Perth.

In another milestone, this weekend the Food and Drug Administration in the United States will hand down a decision on whether to approve MDMA for the treatment of PTSD. Lobbying in the US has intensified in the lead-up to the decision. It will have a big impact on Australia, which is ahead of the rest of the world with treatments.

“FDA approval will mark a tremendous shift in attitude towards these drugs from the ‘war on drugs’ to now suddenly be an approved medication. It will stimulate investment in the sector and give people the confidence to wade back in,” says Michael Winlo, the managing director of ASX-listed Emyria, which is backed by the Forrest family.

“For us in Australia, it is further reassurance that we are moving in the right direction and this represents a brand-new way of tackling mental health. Australia has given itself a head start.”

In January the West Australian company, which received $5 million from the Forrest family’s investment vehicle Tattarang in 2021, received authorised prescriber status from the TGA. It makes money from data collection and research, as well as treatments at its 10-room centre in Perth. It has trained about 20 clinicians and has begun treatments for 12 patients so far.

“Andrew Forrest has been a supporter of ours for a couple of years and really liked the model, which provides services which are generating knowledge that supports innovation,” Winlo, a medical doctor, says.

Other big names in business are getting behind the use of psychedelics to treat what is being described as a mental health epidemic at a time when treatments such as prescription medicines often fail to deliver results.

JJ Wilson, the 35-year-old son of billionaire Chip Wilson, who founded the Lululemon yoga apparel empire, has invested millions of dollars of his own money into a Canadian company that is producing MDMA and natural psilocybin capsules for export.

Last month, Optimi Health, listed in Canada with a market capitalisation of about $30 million, received export permits and started shipments of drugs to Australia under a supply deal with Hunt’s Mind Medicine. “Australia really is the first arguably open market where there is a patient-approved product. It is a very open approach, which is very cool,” Wilson says by phone from his home in Vancouver.

“The Netherlands is tracking in that direction, but the US is taking longer to move forward. The momentum is coming, and different countries are becoming more open to the idea that people need help, people are suffering.”

Wilson, who has described psychedelics as the “new yoga”, has founded several lifestyle companies since he learnt the ropes as a 15-yearold when his dad pulled him out of school to go on a Lululemon roadshow.

He first heard about psychedelics from friends during the COVID-19 pandemic and became convinced their use treating mental health problems was a huge business opportunity. Wilson will visit Sydney, where his family has a beach house in Bronte, in January to assess the market.

While Wilson’s company is one of the few suppliers in the world that can legally manufacture and supply psychedelics, obtaining the drugs is the least of the industry’s worries. The push to legalise the unconventional treatments has been fraught with regulatory delays and controversy. One hurdle is the high cost of the treatments, and providers and charities are trying to find ways to make it accessible to lower-income Australians who are often worst hit by mental illness.

A full program of treatment at Emyria’s Perth clinic costs just under $30,000. This includes about 90 hours with therapists and specialists, which accounts for most of the cost.

There is a strict initial screening process before patients undergo a “dosing”. This involves two therapists sitting with a patient for eight to 10 hours in a specially prepared room. This is repeated two more times over a 12 to 16-week program and there are extensive follow-ups. The process for treating patients with psilocybin also involves two therapists being present for eight hours, with the total cost about $20,000 over three months.

Chris Raine, the co-founder of Clean Slate Clinic, which uses telehealth to treat people struggling with alcohol abuse, says he hopes to give disadvantaged people living in regional areas access to the treatments.

“I would love to open [a clinic] in regional Australia rather than the city, and I’m having various conversations about that. The current structure makes it very expensive to access, and it is not covered by insurance,” says Raine, who recently returned to Australia from the US where he has been studying psychedelic therapy.

Mind Medicine is an industry pioneer, but it has also come under heavy scrutiny after the ABC’s Four Corners in 2022 made allegations of abuse and malpractice, which Hunt and De Jong have denied. There has also been criticism from within the medical industry of the intensive lobbying of the TGA, which received almost 13,000 submissions during its approval process.

Rossell is critical of the submission process, saying the sceptics had their concerns drowned out by an effective lobbying campaign. She says while the treatments work for some patients, up to 30 per cent can experience a “bad trip” or other negative impacts.

Hunt disagrees. “Every now and then, we get a barb that Peter, investment banker, must be seeking to make money from this in some way. We are not. This is purely philanthropic,” he says. “The people who got upset had huge vested interests in the status quo.

“The challenge we have in our mental health system is that it is not a very good system in terms of treatment outcomes. People with depression have a one-third chance of going back into remission.”

The global market for conventional mental health drug treatments is worth about $25 billion, but they are often not effective in treating the soaring rate of mental illness. Mental health is now the most prevalent chronic condition in Australia, according to the Australian Bureau of Statistics. “When you look at the numbers of people with depression or PTSD the potential of the market is enormous,” Hunt says.

Another Perth-based company, Reset Mind Sciences, is also investing in psychedelic therapies. It is a subsidiary of Rinehart-backed, ASX-listed Little Green Pharma. In February, it was forced to withdraw a fund-raising offer because funds in the United Kingdom are banned from investing in psychedelic-assisted psychotherapy. That decision highlights some of the funding challenges facing the industry.

The looming FDA decision may also shift the dial. Winlo says: “It is going to provide confidence in the eyes of payers, our regulator and providers that there is something – and I can say from first-hand experience how impactful it can be, and in some instances it is absolutely transformational.”